Stem cell therapy for cardiovascular diseases: A progressive journey

Current Opinion in Cardiology

Volumn 30, Issue 3, 2015, Pages 205-212

  Willerson, James T ^a  

^a TEXAS HEART INSTITUTE   (United States)

Author keywords

ischemic cardiomyopathy; myocardial infarction; nonischemic cardiomyopathy; refractory angina; stem cell therapy

Indexed keywords

ACUTE DISEASE; ADULT STEM CELL; ANGINA PECTORIS; BONE MARROW DERIVED MONONUCLEAR CELL; CARDIAC STEM CELL; CARDIOVASCULAR DISEASE; CHRONIC DISEASE; CLINICAL TRIAL (TOPIC); FOLLOW UP; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE ENDSYSTOLIC VOLUME; HEART LEFT VENTRICLE FUNCTION; HOSPITAL ADMISSION; HOSPITAL READMISSION; HUMAN; MESENCHYME CELL; PRIORITY JOURNAL; REFRACTORY ANGINA; REVIEW; STEM CELL TRANSPLANTATION; MYOCARDIAL INFARCTION;

ANGINA PECTORIS; HEART FAILURE; HUMANS; MYOCARDIAL INFARCTION; STEM CELL TRANSPLANTATION;

EID: 84928562460     PISSN: 02684705     EISSN: 15317080     Source Type: Journal    
DOI: 10.1097/HCO.0000000000000156     Document Type: Review

References (38)

1. Perin EC, Dohmann HF, Borojevic R, et al. Transendocardial, autologous bone marrow cell transplantation for severe, chronic ischemic heart failure. Circulation 2003; 107:2294-2302.
2. Fisher SA, Brunskill SJ, Doree C, et al. Stem cell therapy for chronic ischaemic heart disease and congestive heart failure. Cochrane Database Syst Rev 2014; 4:CD007888.
3. Perin EC, Willerson JT, Pepine CJ, et al. Effect of transendocardial delivery of autologous bone marrow mononuclear cells on functional capacity, left ventricular function, and perfusion in chronic heart failure: The FOCUSCCTRN trial. JAMA 2012; 307:1717-1726.
4. Poglajen G, Sever M, Cukjati M, et al. Effects of transendocardial CD34 cell transplantation in patients with ischemic cardiomyopathy. Circ Cardiovasc Interv 2014; 7:552-559.
5. Perin EC, Silva GV, Zheng Y, et al. Randomized, double-blind pilot study of transendocardial injection of autologous aldehyde dehydrogenase-bright stem cells in patients with ischemic heart failure. Am Heart J 2012; 163:415-421.
6. Perin EC, Sanz-Ruiz R, Sanchez PL, et al. Adipose-derived regenerative cells in patients with ischemic cardiomyopathy: The PRECISE Trial. Am Heart J 2014; 168:88-95.
7. Bolli R, Chugh AR, D'Amario D, et al. Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO): initial results of a randomised phase 1 trial. Lancet 2011; 378:1847-1857.
8. Chugh AR, Beache GM, Loughran JH, et al. Administration of cardiac stem cells in patients with ischemic cardiomyopathy: The SCIPIO trial: surgical aspects and interim analysis of myocardial function and viability by magnetic resonance. Circulation 2012; 126:S54-64.
9. Vrtovec B, Poglajen G, Sever M, et al. Effects of intracoronary stem cell transplantation in patients with dilated cardiomyopathy. J Card Fail 2011; 17:272-281.
10. Vrtovec B, Poglajen G, Lezaic L, et al. Effects of intracoronary CD34 stem cell transplantation in nonischemic dilated cardiomyopathy patients: 5-year follow-up. Circ Res 2013; 112:165-173.
11. Vrtovec B, Poglajen G, Lezaic L, et al. Comparison of transendocardial and intracoronary CD34 cell transplantation in patients with nonischemic dilated cardiomyopathy. Circulation 2013; 128:S42-49.
12. Wang JA, Xie XJ, He H, et al. A prospective, randomized, controlled trial of autologous mesenchymal stem cells transplantation for dilated cardiomyopathy [in Chinese]. Zhonghua Xin Xue Guan Bing Za Zhi 2006; 34:107-110.
13. Schachinger V, Erbs S, Elsasser A, et al. Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction. N Engl J Med 2006; 355:1210-1221.
14. Assmus B, Rolf A, Erbs S, et al. Clinical outcome 2 years after intracoronary administration of bone marrow-derived progenitor cells in acute myocardial infarction. Circ Heart Fail 2010; 3:89-96.
15. Schachinger V, Erbs S, Elsasser A, et al. Improved clinical outcome after intracoronary administration of bone-marrow-derived progenitor cells in acute myocardial infarction: final 1-year results of the REPAIR-AMI trial. Eur Heart J 2006; 27:2775-2783.
16. Makkar RR, Smith RR, Cheng K, et al. Intracoronary cardiosphere-derived cells for heart regeneration after myocardial infarction (CADUCEUS): A prospective, randomised phase 1 trial. Lancet 2012; 379:895-904.
17. Malliaras K, Makkar RR, Smith RR, et al. Intracoronary cardiosphere-derived cells after myocardial infarction: evidence of therapeutic regeneration in the final 1-year results of the CADUCEUS trial (CArdiosphere-Derived aUtologous stem CElls to reverse ventricUlar dySfunction). J Am Coll Cardiol 2014; 63:110-122.
18. Smith RR, Barile L, Cho HC, et al. Regenerative potential of cardiospherederived cells expanded from percutaneous endomyocardial biopsy specimens. Circulation 2007; 115:896-908.
19. Hirsch A, Nijveldt R, van der Vleuten PA, et al. Intracoronary infusion of mononuclear cells from bone marrow or peripheral blood compared with standard therapy in patients after acute myocardial infarction treated by primary percutaneous coronary intervention: results of the randomized controlled HEBE trial. Eur Heart J 2011; 32:1736-1747.
20. Traverse JH, Henry TD, Ellis SG, et al. Effect of intracoronary delivery of autologous bone marrow mononuclear cells 2 to 3 weeks following acute myocardial infarction on left ventricular function: The LateTIME randomized trial. JAMA 2011; 306:2110-2119.
21. Traverse JH, Henry TD, Pepine CJ, et al. Effect of the use and timing of bone marrow mononuclear cell delivery on left ventricular function after acute myocardial infarction: The TIME randomized trial. JAMA 2012; 308:2380-2389.
22. Losordo DW, Henry TD, Davidson C, et al. Intramyocardial, autologous CD34 cell therapy for refractory angina. Circ Res 2011; 109:428-436.
23. Mathiasen AB, Haack-Sorensen M, Jorgensen E, Kastrup J. Autotransplantation of mesenchymal stromal cells from bone-marrow to heart in patients with severe stable coronary artery disease and refractory angina-final 3-year follow-up. Int J Cardiol 2013; 170:246-251.
24. Beeres SL, Bax JJ, Dibbets-Schneider P, et al. Sustained effect of autologous bone marrow mononuclear cell injection in patients with refractory angina pectoris and chronic myocardial ischemia: twelve-month follow-up results. Am Heart J 2006; 152:684.
25. Vicario J, Campos C, Piva J, et al. Transcoronary sinus administration of autologous bone marrow in patients with chronic refractory stable angina Phase 1. Cardiovasc Radiat Med 2004; 5:71-76.
26. Dimmeler S, Leri A. Aging and disease as modifiers of efficacy of cell therapy. Circ Res 2008; 102:1319-1330.
27. Perin EC, Silva GV, Henry TD, et al. A randomized study of transendocardial injection of autologous bone marrow mononuclear cells and cell function analysis in ischemic heart failure (FOCUS-HF). Am Heart J 2011; 161:1078-1087.
28. Fadini GP, Miorin M, Facco M, et al. Circulating endothelial progenitor cells are reduced in peripheral vascular complications of type 2 diabetes mellitus. J Am Coll Cardiol 2005; 45:1449-1457.
29. Kissel CK, Lehmann R, Assmus B, et al. Selective functional exhaustion of hematopoietic progenitor cells in the bone marrow of patients with postinfarction heart failure. J Am Coll Cardiol 2007; 49:2341-2349.
30. Kondo T, Hayashi M, Takeshita K, et al. Smoking cessation rapidly increases circulating progenitor cells in peripheral blood in chronic smokers. Arterioscler Thromb Vasc Biol 2004; 24:1442-1447.
31. Pirro M, Schillaci G, Menecali C, et al. Reduced number of circulating endothelial progenitors and HOXA9 expression in CD34 cells of hypertensive patients. J Hypertens 2007; 25:2093-2099.
32. Thum T, Fraccarollo D, Schultheiss M, et al. Endothelial nitric oxide synthase uncoupling impairs endothelial progenitor cell mobilization and function in diabetes. Diabetes 2007; 56:666-674.
33. Wohrle J, von Scheidt F, Schauwecker P, et al. Impact of cell number and microvascular obstruction in patients with bone-marrow derived cell therapy: final results from the randomized, double-blind, placebo controlled intracoronary Stem Cell therapy in patients with Acute Myocardial Infarction (SCAMI) trial. Clin Res Cardiol 2013; 102:765-770.
34. Assmus B, Tonn T, Seeger FH, et al. Red blood cell contamination of the final cell product impairs the efficacy of autologous bone marrow mononuclear cell therapy. J Am Coll Cardiol 2010; 55:1385-1394.
35. Perin EC, Dib N, DeMaria A, et al. 2011 Late-breaking clinical trial/clinical science: A phase II dose-escalation study of allogeneic mesenchymal precursor cells in patients with ischemic and nonischemic heart failure [abstract]. Circulation 2011; 124:2372.
36. Nguyen N, Sussman MA. Rejuvenating the senescent heart. Curr Opin Cardiol 2015; 30:235-239.
37. Williams AR, Hatzistergos KE, Addicott B, et al. Enhanced effect of combining human cardiac stem cells and bone marrow mesenchymal stem cells to reduce infarct size and to restore cardiac function after myocardial infarction. Circulation 2013; 127:213-223.
38. Dill T, Schachinger V, Rolf A, et al. Intracoronary administration of bone marrow-derived progenitor cells improves left ventricular function in patients at risk for adverse remodeling after acute ST-segment elevation myocardial infarction: results of the Reinfusion of Enriched Progenitor cells And Infarct Remodeling in Acute Myocardial Infarction study (REPAIR-AMI) cardiac magnetic resonance imaging substudy. Am Heart J 2009; 157:541-547.